Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rosuvastatin
Drug ID BADD_D01971
Description Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406]
Indications and Usage Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease.
Marketing Status Prescription
ATC Code C10AA07
DrugBank ID DB01098
KEGG ID D08492
MeSH ID D000068718
PubChem ID 446157
TTD Drug ID D0JE2E
NDC Product Code 47335-986; 31722-883; 49252-064; 47335-985; 50268-710; 16729-285; 70518-1601; 50268-709; 71335-1446; 47335-984; 69238-1148; 68382-629; 71335-0749; 61919-786; 16729-286; 50090-3177; 16729-284; 50268-711; 70771-1484; 31722-882; 50090-2724; 31722-884; 68071-2326; 31722-885; 70518-1219; 70771-1482; 70771-1481; 49252-062; 70518-0986; 70771-1483; 71335-0606; 50228-117; 47335-987; 68382-628; 68382-627; 16729-287; 68788-7971; 50228-118; 50228-119; 49252-061; 68788-7673; 50228-116; 50090-4909; 72189-065; 49252-063; 50090-2725; 69238-1147; 70269-400; 69238-1146; 71205-044; 68382-630; 70518-1384; 69238-1149
Synonyms Rosuvastatin Calcium | Calcium, Rosuvastatin | Crestor | Rosuvastatin | ZD4522 | ZD 4522
Chemical Information
Molecular Formula C22H28FN3O6S
CAS Registry Number 287714-41-4
SMILES CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.000132%Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.0060.000221%Not Available
Coronary artery stenosis02.02.01.010; 24.04.04.0170.000177%Not Available
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.0130.000132%Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000088%
Cystitis20.03.02.002; 11.01.14.001--
Deafness04.02.01.0010.000221%Not Available
Death08.04.01.001--
Dehydration14.05.05.0010.001192%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.000442%Not Available
Depressed mood19.15.02.0010.000221%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.0020.000132%
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000177%
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.0010.000177%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.001325%Not Available
Diabetes mellitus inadequate control05.06.01.004; 14.06.01.0040.000132%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.000265%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000046%
Dissociation19.14.01.0020.000088%Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 22 Pages